Clearside Biomedical, a clinical-stage company specializing in eye-disease treatments, has filed for Chapter 11 bankruptcy in Delaware, launching a high-stakes bid to sell the business while navigating a widening financial gap that has left the biotech firm with more liabilities than lifelines.

A Desperate Filing Amid a Deepening Financial Hole

The company’s late-Sunday filing reveals $8.7 million in assets against a towering $64 million in liabilities, according to documents attached to its petition. Clearside—known for supplying medical technology to Bausch + Lomb and other major ophthalmic product makers—told the court it plans to establish a structured auction process for its intellectual property.

CEO George Lasezkay said in a Monday statement that despite the company’s troubles, its core technologies remain highly valuable.
“We believe that we have attractive assets based on our clinically proven SCS Microinjector platform and associated intellectual property,” Lasezkay said.

The Technology at the Center of the Fight

Clearside’s most prominent innovation is its suprachoroidal space (SCS) microinjector, a device designed to deliver drugs to the back of the eye without surgery—an approach the company says can revolutionize treatment for several retinal diseases. In a first-day declaration, Lasezkay emphasized that the platform has shown compelling clinical potential and remains a cornerstone of the company’s value.

Advisors and Court Oversight

Clearside has tapped industry heavyweights to steer its restructuring:

• Cooley LLP and Richards, Layton & Finger PA as bankruptcy counsel

• Berkeley Research Group LLC as financial restructuring adviser

The case was assigned to U.S. Bankruptcy Judge Thomas M. Horan, who will oversee the company’s efforts to stabilize operations, market its assets, and potentially secure a buyer capable of carrying the technology forward.

A Sale That Could Define the Company’s Future

While Clearside enters Chapter 11 under pressure, the company’s leadership maintains that its platform—built on years of research—may still find a new life in the hands of a strategic acquirer. For now, the biotech firm’s fate hinges on a bankruptcy-court auction where its vision for the future will be measured against the market’s appetite for cutting-edge ophthalmic technology.